ProQR’s QR-421a Receives FDA’s Rare Pediatric Disease Designation for Retinitis Pigmentosa

 ProQR’s QR-421a Receives FDA’s Rare Pediatric Disease Designation for Retinitis Pigmentosa

ProQR’s QR-421a Receives FDA’s Rare Pediatric Disease Designation for Retinitis Pigmentosa

Shots:

  • The US FDA has granted RPD to the QR-421a for the treatment of patients with retinitis pigmentosa caused by mutations in exon 13 of the USH2A gene
  • The RPD designation provides PR voucher by the FDA to the sponsor, that voucher can be redeemed to receive FDA’s PR designation for any subsequent MAA for a different product
  • QR-421a (IVT) is a first-in-class investigational RNA-based oligonucleotide addressing the underlying cause of vision loss in Usher syndrome type 2 and non-syndromic RP due to mutations in exon 13 of the USH2A gene and has received FDA’s ODD and EU’s FT designation

Click here ­to­ read full press release/ article | Ref: ProQR | Image: ProQR

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post